Literature DB >> 35693392

Is it necessary to target lipid metabolism in different organs for effective treatment of NASH?-the results of the Pan-PPAR Lanifibranor trial.

Amalia Gastaldelli1.   

Abstract

Entities:  

Year:  2022        PMID： 35693392      PMCID： PMC9186198          DOI： 10.21037/hbsn-21-569

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   8.265


× No keyword cloud information.
  9 in total

1.  Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction.

Authors:  Paulina Pettinelli; Luis A Videla
Journal:  J Clin Endocrinol Metab       Date:  2011-02-16       Impact factor: 5.958

2.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta.

Authors:  B M Forman; J Chen; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

3.  A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.

Authors:  Sven M Francque; Pierre Bedossa; Vlad Ratziu; Quentin M Anstee; Elisabetta Bugianesi; Arun J Sanyal; Rohit Loomba; Stephen A Harrison; Rozalina Balabanska; Lyudmila Mateva; Nicolas Lanthier; Naim Alkhouri; Christophe Moreno; Jörn M Schattenberg; Diana Stefanova-Petrova; Luisa Vonghia; Régine Rouzier; Maeva Guillaume; Alexander Hodge; Manuel Romero-Gómez; Philippe Huot-Marchand; Martine Baudin; Marie-Paule Richard; Jean-Louis Abitbol; Pierre Broqua; Jean-Louis Junien; Manal F Abdelmalek
Journal:  N Engl J Med       Date:  2021-10-21       Impact factor: 91.245

4.  Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.

Authors:  Zoe Boyer-Diaz; Peio Aristu-Zabalza; María Andrés-Rozas; Claude Robert; Martí Ortega-Ribera; Anabel Fernández-Iglesias; Pierre Broqua; Jean-Louis Junien; Guillaume Wettstein; Jaime Bosch; Jordi Gracia-Sancho
Journal:  J Hepatol       Date:  2020-12-02       Impact factor: 25.083

Review 5.  Liver-targeting drugs and their effect on blood glucose and hepatic lipids.

Authors:  Amalia Gastaldelli; Norbert Stefan; Hans-Ulrich Häring
Journal:  Diabetologia       Date:  2021-04-20       Impact factor: 10.122

Review 6.  Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis.

Authors:  Sara Guerra; Gabriele Mocciaro; Amalia Gastaldelli
Journal:  Eur J Clin Invest       Date:  2021-12-07       Impact factor: 4.686

7.  Identification of Lineage-Specific Transcription Factors That Prevent Activation of Hepatic Stellate Cells and Promote Fibrosis Resolution.

Authors:  Xiao Liu; Jun Xu; Sara Rosenthal; Ling-Juan Zhang; Ryan McCubbin; Nairika Meshgin; Linshan Shang; Yukinori Koyama; Hsiao-Yen Ma; Sonia Sharma; Sven Heinz; Chris K Glass; Chris Benner; David A Brenner; Tatiana Kisseleva
Journal:  Gastroenterology       Date:  2020-01-23       Impact factor: 33.883

8.  PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH.

Authors:  Amalia Gastaldelli; Silvia Sabatini; Fabrizia Carli; Melania Gaggini; Fernando Bril; Renata Belfort-DeAguiar; Vincenzo Positano; Diana Barb; Sushma Kadiyala; Stephen Harrison; Kenneth Cusi
Journal:  Liver Int       Date:  2021-07-21       Impact factor: 8.754
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.